These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20414586)

  • 1. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial.
    Silva RC; Saute JA; Silva AC; Coutinho AC; Saraiva-Pereira ML; Jardim LB
    Braz J Med Biol Res; 2010 Jun; 43(6):537-42. PubMed ID: 20414586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression and clinical progression in spinocerebellar ataxias.
    Lo RY; Figueroa KP; Pulst SM; Perlman S; Wilmot G; Gomez C; Schmahmann J; Paulson H; Shakkottai VG; Ying S; Zesiewicz T; Bushara K; Geschwind M; Xia G; Yu JT; Lee LE; Ashizawa T; Subramony SH; Kuo SH
    Parkinsonism Relat Disord; 2016 Jan; 22():87-92. PubMed ID: 26644294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatigue and Its Associated Factors in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
    Martinez AR; Nunes MB; Faber I; D'Abreu A; Lopes-Cendes Í; França MC
    Cerebellum; 2017 Feb; 16(1):118-121. PubMed ID: 27021342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bidirectional Connections between Depression and Ataxia Severity in Spinocerebellar Ataxia Type 3 Patients.
    Lin MT; Yang JS; Chen PP; Qian MZ; Lin HX; Chen XP; Shang XJ; Wang DN; Chen YC; Jiang B; Chen YJ; Chen WJ; Wang N; Gan SR
    Eur Neurol; 2018; 79(5-6):266-271. PubMed ID: 29763923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive cognitive dysfunction in spinocerebellar ataxia type 3.
    Roeske S; Filla I; Heim S; Amunts K; Helmstaedter C; Wüllner U; Wagner M; Klockgether T; Minnerop M
    Mov Disord; 2013 Sep; 28(10):1435-8. PubMed ID: 23736996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance Between Patient-Reported Outcomes and Physician-Rated Motor Symptom Severity in Early-to-Middle-Stage Spinocerebellar Ataxia Type 3.
    Maas RPPWM; Schutter DJLG; van de Warrenburg BPC
    Cerebellum; 2021 Dec; 20(6):887-895. PubMed ID: 33694049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance spectroscopy of the cerebellum in patients with spinocerebellar ataxia type 3/Machado-Joseph disease.
    Lei L; Liao Y; Liao W; Zhou J; Yuan Y; Wang J; Jiang H; Shen L; Tang B
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 36(6):511-9. PubMed ID: 21743142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias.
    Jacobi H; du Montcel ST; Bauer P; Giunti P; Cook A; Labrum R; Parkinson MH; Durr A; Brice A; Charles P; Marelli C; Mariotti C; Nanetti L; Sarro L; Rakowicz M; Sulek A; Sobanska A; Schmitz-Hübsch T; Schöls L; Hengel H; Baliko L; Melegh B; Filla A; Antenora A; Infante J; Berciano J; van de Warrenburg BP; Timmann D; Szymanski S; Boesch S; Nachbauer W; Kang JS; Pandolfo M; Schulz JB; Melac AT; Diallo A; Klockgether T
    J Neurol; 2018 Sep; 265(9):2040-2051. PubMed ID: 29959555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence.
    Donis KC; Saute JA; Krum-Santos AC; Furtado GV; Mattos EP; Saraiva-Pereira ML; Torman VL; Jardim LB
    Neurogenetics; 2016 Apr; 17(2):107-13. PubMed ID: 26780339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease.
    Matilla T; McCall A; Subramony SH; Zoghbi HY
    Ann Neurol; 1995 Jul; 38(1):68-72. PubMed ID: 7611728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled pilot trial of game-based training in individuals with spinocerebellar ataxia type 3.
    Wang RY; Huang FY; Soong BW; Huang SF; Yang YR
    Sci Rep; 2018 May; 8(1):7816. PubMed ID: 29777115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial.
    Saute JA; Rieder CR; Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; Souza DO; Saraiva-Pereira ML; Portela LV; Camey S; Torman VB; Jardim LB
    J Neurol Sci; 2015 Nov; 358(1-2):72-6. PubMed ID: 26297649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.
    Jacobi H; du Montcel ST; Bauer P; Giunti P; Cook A; Labrum R; Parkinson MH; Durr A; Brice A; Charles P; Marelli C; Mariotti C; Nanetti L; Panzeri M; Rakowicz M; Sulek A; Sobanska A; Schmitz-Hübsch T; Schöls L; Hengel H; Baliko L; Melegh B; Filla A; Antenora A; Infante J; Berciano J; van de Warrenburg BP; Timmann D; Szymanski S; Boesch S; Kang JS; Pandolfo M; Schulz JB; Molho S; Diallo A; Klockgether T
    Lancet Neurol; 2015 Nov; 14(11):1101-8. PubMed ID: 26377379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind placebo-controlled trial of the effects of oral trehalose in spinocerebellar ataxia type 3: An interim analysis.
    Yap KH; Azmin S; Abdul Manan H; Yahya N; Ahmad N; Tajurudin FW; Mat Desa SH; van de Warrenburg B; Mohamed Mukari SA; Achok HN; Ahmad Damanhuri H; Rani R; Mohamed Ibrahim N
    Parkinsonism Relat Disord; 2024 Jul; 124():107013. PubMed ID: 38843619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressive symptoms in Machado-Joseph disease (SCA3) patients and their relatives.
    Cecchin CR; Pires AP; Rieder CR; Monte TL; Silveira I; Carvalho T; Saraiva-Pereira ML; Sequeiros J; Jardim LB
    Community Genet; 2007; 10(1):19-26. PubMed ID: 17167246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of speech therapy on quality of life in patients with spinocerebelar ataxia type 3.
    Diaféria G; Bommarito S; Braga Neto P; Park SW; Padovani M; Haddad F; Haddad L; Voos MC; Chien HF; Pedroso JL; Barsottini O
    Arq Neuropsiquiatr; 2022 Oct; 80(10):1017-1025. PubMed ID: 36535286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy.
    Rüb U; Seidel K; Ozerden I; Gierga K; Brunt ER; Schöls L; de Vos RA; den Dunnen W; Schultz C; Auburger G; Deller T
    Brain Res Rev; 2007 Feb; 53(2):235-49. PubMed ID: 17014911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines in Machado Joseph Disease/Spinocerebellar Ataxia 3.
    da Silva Carvalho G; Saute JA; Haas CB; Torrez VR; Brochier AW; Souza GN; Furtado GV; Gheno T; Russo A; Monte TL; Schumacher-Schuh A; D'Avila R; Donis KC; Castilhos RM; Souza DO; Saraiva-Pereira ML; Torman VL; Camey S; Portela LV; Jardim LB
    Cerebellum; 2016 Aug; 15(4):518-25. PubMed ID: 26395908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor for the treatment of spinocerebellar ataxia type 3: an open-label study.
    Tan S; Wang RH; Niu HX; Shi CH; Mao CY; Zhang R; Song B; Sun SL; Liu XJ; Hou HM; Liu YT; Gao Y; Fang H; Kong XD; Xu YM
    Chin Med J (Engl); 2015 Feb; 128(3):291-4. PubMed ID: 25635421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occupational therapy to improve quality of life for colorectal cancer survivors: a randomized clinical trial.
    Yang SY; Wang JD; Chang JH
    Support Care Cancer; 2020 Mar; 28(3):1503-1511. PubMed ID: 31273505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.